HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc. (HBIO) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: March 17, 2026 , by DENELSKY STEPHEN J .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| DENELSKY STEPHEN J | Director | Buy | 10,000 | $4.87 | $48.7K | 21,000 | |
| Snider William | Director | Buy | 8,475 | $4.85 | $41.1K | 32,000 | |
| Snider William | Director | Buy | 12,525 | $4.99 | $62.5K | 23,525 | |
| Duke John D | Chief Executive Officer | Buy | 5,000 | $5.01 | $25.1K | 105,000 | |
| Frost Mark T | Chief Financial Officer | Buy | 5,000 | $5.00 | $25.0K | 17,500 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.